St3gal5 - ST3 beta-galactoside alpha-2,3-sialyltransferase 5 Gene
Also Known as Siat9
Species: Rattus norvegicus
Summary
Predicted to enable lactosylceramide alpha-2,3-sialyltransferase activity. Predicted to be involved in protein glycosylation. Predicted to be located in Golgi membrane. Predicted to be integral component of membrane. Human ortholog(s) of this gene implicated in salt and pepper syndrome. Orthologous to human ST3GAL5 (ST3 beta-galactoside alpha-2,3-sialyltransferase 5). [provided by Alliance of Genome Resources, Apr 2022]
St3gal5 Products (4)
| mRNA | Protein | Name |
|---|---|---|
| NM_001398712.1 | NP_001385641.1 | lactosylceramide alpha-2,3-sialyltransferase isoform 1 |
| NM_001398713.1 | NP_001385642.1 | lactosylceramide alpha-2,3-sialyltransferase isoform 2 |
| NM_001398714.1 | NP_001385643.1 | lactosylceramide alpha-2,3-sialyltransferase isoform 3 |
| NM_031337.3 | NP_112627.2 | lactosylceramide alpha-2,3-sialyltransferase isoform 2 |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
lactosylceramide alpha-2,3-sialyltransferase |
|
|
Related Agents
- Clinical Phase
- Pre-clinical Phase
Clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-W013053 | Dibenz[a,h]anthracene | Inducer | 98.0% | Phase 3 |
Pre-clinical Phase
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-E70299 | ST3 β-Gal α-2,3-Sialyltransferase 5 | Inhibitor | / | Unkown |
| HY-RS13850 | ST3GAL5 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service